€231.7m market cap

€11.8 last close

Nanobiotix is a French nanomedicine company developing NBTXR3 for the treatment of cancer, which interacts with ionizing radiation to locally increase the energy. NBTXR3 is in pivotal clinical development in STS in Europe and is partnered with PharmaEngine in Asia-Pacific.

Investment summary

Nanobiotix has made progress with NBTXR3 as a standalone agent to enhance radiation therapy and now has clinical data from three cancers demonstrating consistent safety, feasibility and transferability of effect across different indications. Nanobiotix has also released preclinical results demonstrating NBTXR3’s ability to enhance the immunogenicity of various cancers, which is the cornerstone idea behind the immuno-oncology (IO) products. We expect an eventful 2017, with several clinical trials reporting results and a potential CE mark approval in mid-2017 for use in soft tissue sarcoma (STS). Our valuation has increased to €738m.

Y/E Dec
Revenue (£m)
PBT (£m)
EPS (p)
P/E (x)
P/CF (x)
2016A 0.5 (11.2) (12.3) (5.20) N/A N/A
2017A 1.3 (9.4) (10.6) (4.46) N/A N/A
2018E 4.7 (5.5) (6.4) (2.43) N/A N/A
2019E N/A N/A N/A N/A N/A N/A
Last updated on 27/11/2018
Share price graph
Balance sheet
Forecast net cash (£m) 7.4
Forecast gearing ratio (%) N/A
Price performance
Actual (12.6) (31.2) (16.6)
Relative* (12.5) (24.0) (10.5)
52-week high/low €18.3/€9.5
*% relative to local index
Key management
Laurent Levy CEO
Philippe Mauberna CFO